opname van eiwitten protein digestion
Conditions
Interventions
Study subjects will receive a product e.g. Fermotein dry, Fermotein wet,
modified Fermotein wet and a reference Mycoprotein. All representing a 20g
protein load in, randomised order.
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Healthy men and women; * Age between 18 and 70 years ; * Having veins suitable for blood sampling via a catheter (judged by study nurse/ medical doctor); * Body mass index (BMI) between 18.5 and 30 kg/m2
Exclusion criteria
Exclusion criteria: * Any metabolic, gastrointestinal, inflammatory or chronic disease (such as diabetes, anaemia, hepatitis, cardiovascular disease),or having a condition or disease that may lead to an impaired immune system * History of gastro-intestinal surgery or having (serious) gastro-intestinal complaints; * History of liver dysfunction (cirrhosis, hepatitis) or liver surgery; * Kidney dysfunction (self-reported); * Any use of medication that may suppress the immune system, this will be judged by the medical supervisor; * Use of medication that may influence the study results, such as gastric acid inhibitors, laxatives, stomach protectors and drugs that can affect intestinal motility, this will be will be judged by the medical supervisor; * Anaemia (Hb values
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the degree of digestibility determined e.g. the appearance of free amino acids in blood samples collected before and after consumption. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are plasma glucose and insulin levels. | — |
Countries
Netherlands
Outcome results
None listed